Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia
暂无分享,去创建一个
E. Kimby | A. Österborg | J. Lundin | H. Mellstedt | E. Rossmann | M. Rezvany | A. Porwit‐MacDonald | C. Karlsson | P. Edman | A. Porwit‐Macdonald